[go: up one dir, main page]

MA33840B1 - Nouveau composé de spiropipéridine - Google Patents

Nouveau composé de spiropipéridine

Info

Publication number
MA33840B1
MA33840B1 MA34993A MA34993A MA33840B1 MA 33840 B1 MA33840 B1 MA 33840B1 MA 34993 A MA34993 A MA 34993A MA 34993 A MA34993 A MA 34993A MA 33840 B1 MA33840 B1 MA 33840B1
Authority
MA
Morocco
Prior art keywords
compound
spiropiperidine compound
novel spiropiperidine
novel
formula
Prior art date
Application number
MA34993A
Other languages
Arabic (ar)
English (en)
Inventor
Chafiq Hamdouchi
Jayana Pankaj Lineswala
Pranab Maiti
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43384775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33840(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA33840B1 publication Critical patent/MA33840B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention porte sur un composé de la formule, ou sur un sel pharmaceutiquement acceptable de celui-ci, ainsi que sur une composition pharmaceutique, et sur un procédé pour traiter le diabète.
MA34993A 2009-11-30 2012-06-21 Nouveau composé de spiropipéridine MA33840B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26518109P 2009-11-30 2009-11-30
PCT/US2010/057359 WO2011066183A1 (fr) 2009-11-30 2010-11-19 Nouveau composé de spiropipéridine

Publications (1)

Publication Number Publication Date
MA33840B1 true MA33840B1 (fr) 2012-12-03

Family

ID=43384775

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34993A MA33840B1 (fr) 2009-11-30 2012-06-21 Nouveau composé de spiropipéridine

Country Status (26)

Country Link
US (1) US8822486B2 (fr)
EP (1) EP2507228B1 (fr)
JP (1) JP5709889B2 (fr)
KR (1) KR101410103B1 (fr)
CN (1) CN102648195B (fr)
AR (1) AR078948A1 (fr)
AU (1) AU2010324987B2 (fr)
BR (1) BR112012012903A2 (fr)
CA (1) CA2781292C (fr)
CL (1) CL2012001321A1 (fr)
CR (1) CR20120296A (fr)
DO (1) DOP2012000139A (fr)
EA (1) EA020507B1 (fr)
EC (1) ECSP12011930A (fr)
ES (1) ES2526568T3 (fr)
GT (1) GT201200164A (fr)
IL (1) IL219594A0 (fr)
MA (1) MA33840B1 (fr)
MX (1) MX2012006233A (fr)
NZ (1) NZ600203A (fr)
PE (1) PE20121474A1 (fr)
PH (1) PH12012501052A1 (fr)
TN (1) TN2012000248A1 (fr)
TW (1) TW201141866A (fr)
WO (1) WO2011066183A1 (fr)
ZA (1) ZA201203055B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8476287B2 (en) 2009-12-25 2013-07-02 Mochida Pharmaceutical Co., Ltd. 3-hydroxy-5-arylisothiazole derivative
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
US8557766B2 (en) 2011-04-27 2013-10-15 Mochida Pharmaceutical Co., Ltd. 3-hydroxyisothiazole 1-oxide derivatives
AU2012248627A1 (en) 2011-04-28 2013-11-14 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
TWI537262B (zh) * 2011-08-17 2016-06-11 美國禮來大藥廠 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物
CA2905726C (fr) * 2013-03-14 2022-05-31 Janssen Pharmaceutica Nv Agonistes de gpr120 pour le traitement du diabete de type 2
HK1221465A1 (zh) 2013-11-14 2017-06-02 Cadila Healthcare Limited 新型杂环化合物
EP3076959B1 (fr) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Composés bicycliques antidiabétiques
EP3102198B1 (fr) 2014-02-06 2020-08-26 Merck Sharp & Dohme Corp. Composés antidiabétiques
WO2018166855A1 (fr) 2017-03-16 2018-09-20 Basf Se Dihydroisoxazoles à substitution hétérobicyclique
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
PT3820572T (pt) 2018-07-13 2023-11-10 Gilead Sciences Inc Inibidores pd-1/pd-l1
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
CN110590767B (zh) * 2019-08-29 2021-10-08 南方科技大学 一种合成amg837的方法
PH12022550852A1 (en) 2019-10-07 2023-05-03 Kallyope Inc Gpr119 agonists
CA3173731A1 (fr) 2020-02-28 2021-09-02 Kallyope, Inc. Agonistes de gpr40
KR20230012597A (ko) 2020-05-19 2023-01-26 칼리오페, 인크. Ampk 활성화제
AU2021297323A1 (en) 2020-06-26 2023-02-16 Kallyope, Inc. AMPK activators

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
BRPI0409078A (pt) 2003-04-04 2006-04-18 Merck & Co Inc composto, métodos para o tratamento ou prevenção de distúrbios, doenças ou condições responsivas à ativação do receptor de melanocortina-4, para o tratamento ou prevenção de obesidade, para o tratamento ou prevenção de um distúrbio relacionado com a obesidade, para o tratamento ou prevenção de diabete melito, para o tratamento ou prevenção da disfunção sexual masculina ou feminina e para o tratamento ou prevenção de disfunção erétil, composição farmacêutica, métodos para o tratamento de disfução erétil em um mamìfero, para o tratamento de diabete em um mamìfero e para o tratamento de obesidade em um mamìfero, e, uso de um composto
JP2007510662A (ja) 2003-11-04 2007-04-26 エリクシアー ファーマシューティカルズ， インコーポレイテッド 治療化合物およびその使用
US7816367B2 (en) 2004-02-27 2010-10-19 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
EP1731505B1 (fr) 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Dérivés de l'acide alkoxyphénylpropanoïque
EP1795527B1 (fr) * 2004-09-07 2009-04-22 Banyu Pharmaceutical Co., Ltd. Composé spiro substitué par un groupement carbamoyle
JP2009543860A (ja) * 2006-07-19 2009-12-10 アストラゼネカ・アクチエボラーグ 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用
AU2007301126A1 (en) * 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
ATE486877T1 (de) * 2006-12-29 2010-11-15 Hoffmann La Roche Azaspiroderivate
EP2139843B1 (fr) * 2007-04-16 2013-12-25 Amgen, Inc Modulateurs de gpr40 des acides biphényle phénoxy, thiophényle et aminophénylpropanoïque substitués
CL2008003153A1 (es) * 2007-10-26 2009-07-24 Japan Tobacco Inc Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras.
AR078522A1 (es) * 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament

Also Published As

Publication number Publication date
EA020507B1 (ru) 2014-11-28
IL219594A0 (en) 2012-06-28
DOP2012000139A (es) 2012-08-15
JP2013512277A (ja) 2013-04-11
ECSP12011930A (es) 2012-07-31
CA2781292A1 (fr) 2011-06-03
EP2507228A1 (fr) 2012-10-10
EP2507228B1 (fr) 2014-11-05
BR112012012903A2 (pt) 2017-03-01
EA201290416A1 (ru) 2012-11-30
KR20120088770A (ko) 2012-08-08
PE20121474A1 (es) 2012-11-05
NZ600203A (en) 2013-09-27
TW201141866A (en) 2011-12-01
CA2781292C (fr) 2014-04-22
GT201200164A (es) 2014-02-27
ES2526568T3 (es) 2015-01-13
PH12012501052A1 (en) 2013-02-04
AU2010324987A1 (en) 2012-07-26
US20120220616A1 (en) 2012-08-30
JP5709889B2 (ja) 2015-04-30
ZA201203055B (en) 2013-09-25
KR101410103B1 (ko) 2014-06-25
WO2011066183A1 (fr) 2011-06-03
AU2010324987B2 (en) 2014-01-30
US8822486B2 (en) 2014-09-02
CN102648195A (zh) 2012-08-22
CL2012001321A1 (es) 2013-11-15
CN102648195B (zh) 2015-01-07
TN2012000248A1 (en) 2013-12-12
CR20120296A (es) 2012-07-16
MX2012006233A (es) 2012-07-03
AR078948A1 (es) 2011-12-14

Similar Documents

Publication Publication Date Title
MA33840B1 (fr) Nouveau composé de spiropipéridine
MA33662B1 (fr) Composés de spiropipéridine et leur utilisation pharmaceutique pour le traitement du diabète
MA35351B1 (fr) Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète.
MA35128B1 (fr) Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite
IN2014MN02106A (fr)
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA35432B1 (fr) Composé pour le traitement et la prophylaxie de la maladie du virus respiratoire syncytial
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
MA37888A1 (fr) Composition pharmaceutique enrobée contenant du régorafenib
MA35275B1 (fr) Composés de tétrahydropyridopyridine et tétrahydropyridopyrimidine et utilisation de ceux-ci en tant que modulateurs de récepteur c5a
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MX2011009796A (es) Inhibidores de la cinasa pi3.
EA201291236A1 (ru) Азотные гетероциклические соединения, применимые в качестве ингибиторов pde10
MA32904B1 (fr) Composes de purine
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA40895A (fr) Synthèse de copanlisib et son sel de dichlorhydrate
EP2666471A4 (fr) Composition pharmaceutique pour la traitement de la rate et de l'estomac, ainsi que procédé de préparation de cette composition
MX2012003007A (es) Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.
MA39048A1 (fr) Nouveaux inhibiteurs de la dgat2
WO2010110545A2 (fr) Nouveau dérivé hydroxamate, procédé de production associé, et composition pharmaceutique comprenant le dérivé
MA39983A (fr) Dérivés de carboxamide
UA103329C2 (ru) Соли соединений-ингибиторов вич
MX2016004265A (es) Combinacion.
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine